Systemic Anti-Cancer Therapy Regimen Library
BR Neoadjuvant - cARBOplatin Q3W and PACLItaxel Q1W followed by AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W
Treatment Overview
This regimen consists of two parts: cARBOplatin Q3W and PACLItaxel Q1W followed by AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W.
This regimen contains a medicine where one or more biosimilars may exist. Any biosimilars used have been reviewed by the regulator (Medsafe) and relevant specialists were consulted nationally. Where regulators, in consultation with relevant specialists, have agreed that there are no clinically significant differences in either safety or effectiveness between a biosimilar and originator product, these drugs may be used interchangeably.
Cycle 1 - 21 days - cARBOplatin Q3W and PACLItaxel Q1W
PACLItaxel: Tapering schedule of pre-medications is for patients who did not experience a hypersensitivity reaction to the previous dose of weekly PACLItaxel.
Cycle specific Supportive Care Factors:
Emetogenicity: HIGH (cARBOplatin AUC≥4) day 1; LOW days 8 and 15.
Growth factor support: Recommended for primary prophylaxis.
Hypersensitivity / Infusion related reaction risk: HIGH - routine premedication recommended.
Cycle 2 - 21 days - cARBOplatin Q3W and PACLItaxel Q1W (tapering hypersensitivity pre-medications)
PACLItaxel: Tapering schedule of pre-medications is for patients who did not experience a hypersensitivity reaction to the previous dose of weekly PACLItaxel.
Cycle specific Supportive Care Factors:
Emetogenicity: HIGH (cARBOplatin AUC≥4) day 1; LOW days 8 and 15.
Growth factor support: Recommended for primary prophylaxis.
Hypersensitivity / Infusion related reaction risk: HIGH - routine premedication recommended.
Cycles 3 to 4 - 21 days - cARBOplatin Q3W and PACLItaxel Q1W (no hypersensitivity pre-medications)
PACLItaxel: Tapering schedule of pre-medications is for patients who did not experience a hypersensitivity reaction to the previous dose of weekly PACLItaxel.
Cycle specific Supportive Care Factors:
Emetogenicity: HIGH (cARBOplatin AUC≥4) day 1; LOW days 8 and 15.
Growth factor support: Recommended for primary prophylaxis.
Cycles 5 to 8 - 21 days - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W
Cycle specific Supportive Care Factors:
Emetogenicity: HIGH.
Cycle details
Cycle 1 - 21 days - cARBOplatin Q3W and PACLItaxel Q1W
Medication | Dose | Route | Days | Max Duration |
---|---|---|---|---|
aprepitant | 125 mg | oral administration | 1 | |
aprepitant | 80 mg | oral administration | 2, 3 | |
dexamethasone * | 8 mg | oral administration | 1, 2, 3 | |
ondansetron | 8 mg | oral administration | 1, 15 | |
loratadine * | 10 mg | oral administration | 1, 8, 15 | |
famotidine * | 20 mg | oral administration | 1, 8, 15 | |
dexamethasone * | 4 mg | oral administration | 8 | |
PACLItaxel * | 80 mg/m² | intravenous | 1, 8, 15 | 60 minutes |
cARBOplatin * | 6 AUC (area under the curve) | intravenous | 1 | 60 minutes |
ondansetron | 8 mg | oral administration | 1 | |
filgrastim | 5 microgram/kg Once daily | subcutaneous injection | 2 to 6 | |
domperidone | 10 mg Three times daily | oral administration | 1 |
PACLItaxel: Tapering schedule of pre-medications is for patients who did not experience a hypersensitivity reaction to the previous dose of weekly PACLItaxel.
Cycle specific Supportive Care Factors:
Emetogenicity: HIGH (cARBOplatin AUC≥4) day 1; LOW days 8 and 15.
Growth factor support: Recommended for primary prophylaxis.
Hypersensitivity / Infusion related reaction risk: HIGH - routine premedication recommended.
Cycle 2 - 21 days - cARBOplatin Q3W and PACLItaxel Q1W (tapering hypersensitivity pre-medications)
Medication | Dose | Route | Days | Max Duration |
---|---|---|---|---|
aprepitant | 125 mg | oral administration | 1 | |
aprepitant | 80 mg | oral administration | 2, 3 | |
dexamethasone * | 8 mg | oral administration | 1, 2, 3 | |
ondansetron | 8 mg | oral administration | 1, 8, 15 | |
loratadine * | 10 mg | oral administration | 1 | |
PACLItaxel * | 80 mg/m² | intravenous | 1, 8, 15 | 60 minutes |
cARBOplatin * | 6 AUC (area under the curve) | intravenous | 1 | 60 minutes |
ondansetron | 8 mg | oral administration | 1 | |
filgrastim | 5 microgram/kg Once daily | subcutaneous injection | 2 to 6 | |
domperidone | 10 mg Three times daily | oral administration | 1 |
PACLItaxel: Tapering schedule of pre-medications is for patients who did not experience a hypersensitivity reaction to the previous dose of weekly PACLItaxel.
Cycle specific Supportive Care Factors:
Emetogenicity: HIGH (cARBOplatin AUC≥4) day 1; LOW days 8 and 15.
Growth factor support: Recommended for primary prophylaxis.
Hypersensitivity / Infusion related reaction risk: HIGH - routine premedication recommended.
Cycles 3 to 4 - 21 days - cARBOplatin Q3W and PACLItaxel Q1W (no hypersensitivity pre-medications)
Medication | Dose | Route | Days | Max Duration |
---|---|---|---|---|
aprepitant | 125 mg | oral administration | 1 | |
aprepitant | 80 mg | oral administration | 2, 3 | |
dexamethasone * | 8 mg | oral administration | 1, 2, 3 | |
ondansetron | 8 mg | oral administration | 1, 8, 15 | |
PACLItaxel * | 80 mg/m² | intravenous | 1, 8, 15 | 60 minutes |
cARBOplatin * | 6 AUC (area under the curve) | intravenous | 1 | 60 minutes |
ondansetron | 8 mg | oral administration | 1 | |
filgrastim | 5 microgram/kg Once daily | subcutaneous injection | 2 to 6 | |
domperidone | 10 mg Three times daily | oral administration | 1 |
PACLItaxel: Tapering schedule of pre-medications is for patients who did not experience a hypersensitivity reaction to the previous dose of weekly PACLItaxel.
Cycle specific Supportive Care Factors:
Emetogenicity: HIGH (cARBOplatin AUC≥4) day 1; LOW days 8 and 15.
Growth factor support: Recommended for primary prophylaxis.
Cycles 5 to 8 - 21 days - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W
Medication | Dose | Route | Days | Max Duration |
---|---|---|---|---|
olanzapine * | 5 mg | oral administration | 1 to 4 | |
aprepitant | 125 mg | oral administration | 1 | |
aprepitant | 80 mg | oral administration | 2, 3 | |
dexamethasone * | 12 mg | oral administration | 1 | |
dexamethasone * | 8 mg | oral administration | 2, 3, 4 | |
ondansetron | 8 mg | oral administration | 1 | |
DOXOrubicin | 60 mg/m² | intravenous | 1 | 15 minutes |
CYCLOPHOSPHamide | 600 mg/m² | intravenous | 1 | 60 minutes |
ondansetron | 8 mg | oral administration | 1 | |
cycliZINE | 50 mg Three times daily | oral administration | 1 |
Cycle specific Supportive Care Factors:
Emetogenicity: HIGH.
Full details
Cycle 1 - 21 days - cARBOplatin Q3W and PACLItaxel Q1W
Day: 1
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
aprepitant | 125 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. |
|
dexamethasone * | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy with food. |
|
ondansetron | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. |
|
loratadine * | 10 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion. |
|
famotidine * | 20 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion. Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine. |
|
PACLItaxel * | 80 mg/m² | intravenous | 60 minutes |
Instructions:
Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size. Please carry out graded challenge as per institutional policy. |
cARBOplatin * | 6 AUC (area under the curve) | intravenous | 60 minutes |
Instructions:
Hypersensitivity risk increases with number of cycles of cARBOplatin. |
ondansetron | 8 mg | oral administration |
Instructions:
EIGHT hours after chemotherapy OR before bed. |
|
domperidone | 10 mg Three times daily | oral administration |
Instructions:
When required for nausea and/or vomiting. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics. |
Day: 2
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
aprepitant | 80 mg | oral administration |
Instructions:
ONCE daily in the morning. |
|
dexamethasone * | 8 mg | oral administration |
Instructions:
ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion. |
|
filgrastim | 5 microgram/kg Once daily | subcutaneous injection |
Instructions:
Round dose to nearest prefilled syringe dose of 300 micrograms or 480 micrograms. |
Day: 3
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
aprepitant | 80 mg | oral administration |
Instructions:
ONCE daily in the morning. |
|
dexamethasone * | 8 mg | oral administration |
Instructions:
ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion. |
|
filgrastim | 5 microgram/kg Once daily | subcutaneous injection |
Instructions:
Round dose to nearest prefilled syringe dose of 300 micrograms or 480 micrograms. |
Day: 4
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
filgrastim | 5 microgram/kg Once daily | subcutaneous injection |
Instructions:
Round dose to nearest prefilled syringe dose of 300 micrograms or 480 micrograms. |
Day: 5
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
filgrastim | 5 microgram/kg Once daily | subcutaneous injection |
Instructions:
Round dose to nearest prefilled syringe dose of 300 micrograms or 480 micrograms. |
Day: 6
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
filgrastim | 5 microgram/kg Once daily | subcutaneous injection |
Instructions:
Round dose to nearest prefilled syringe dose of 300 micrograms or 480 micrograms. |
Day: 8
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
loratadine * | 10 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion. |
|
famotidine * | 20 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion. Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine. |
|
dexamethasone * | 4 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion with food. |
|
PACLItaxel * | 80 mg/m² | intravenous | 60 minutes |
Instructions:
Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size. Please carry out graded challenge as per institutional policy. |
Day: 15
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
ondansetron | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. Alternative is dexamethasone 4 mg. |
|
loratadine * | 10 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion. |
|
famotidine * | 20 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion. Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine. |
|
PACLItaxel * | 80 mg/m² | intravenous | 60 minutes |
Instructions:
Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size. Please carry out graded challenge as per institutional policy. |
Cycle 2 - 21 days - cARBOplatin Q3W and PACLItaxel Q1W (tapering hypersensitivity pre-medications)
Day: 1
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
aprepitant | 125 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. |
|
dexamethasone * | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy with food. |
|
ondansetron | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. |
|
loratadine * | 10 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion. |
|
PACLItaxel * | 80 mg/m² | intravenous | 60 minutes |
Instructions:
Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size. Please carry out graded challenge as per institutional policy. |
cARBOplatin * | 6 AUC (area under the curve) | intravenous | 60 minutes |
Instructions:
Hypersensitivity risk increases with number of cycles of cARBOplatin. |
ondansetron | 8 mg | oral administration |
Instructions:
EIGHT hours after chemotherapy OR before bed. |
|
domperidone | 10 mg Three times daily | oral administration |
Instructions:
When required for nausea and/or vomiting. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics. |
Day: 2
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
aprepitant | 80 mg | oral administration |
Instructions:
ONCE daily in the morning. |
|
dexamethasone * | 8 mg | oral administration |
Instructions:
ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion. |
|
filgrastim | 5 microgram/kg Once daily | subcutaneous injection |
Instructions:
Round dose to nearest prefilled syringe dose of 300 micrograms or 480 micrograms. |
Day: 3
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
aprepitant | 80 mg | oral administration |
Instructions:
ONCE daily in the morning. |
|
dexamethasone * | 8 mg | oral administration |
Instructions:
ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion. |
|
filgrastim | 5 microgram/kg Once daily | subcutaneous injection |
Instructions:
Round dose to nearest prefilled syringe dose of 300 micrograms or 480 micrograms. |
Day: 4
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
filgrastim | 5 microgram/kg Once daily | subcutaneous injection |
Instructions:
Round dose to nearest prefilled syringe dose of 300 micrograms or 480 micrograms. |
Day: 5
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
filgrastim | 5 microgram/kg Once daily | subcutaneous injection |
Instructions:
Round dose to nearest prefilled syringe dose of 300 micrograms or 480 micrograms. |
Day: 6
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
filgrastim | 5 microgram/kg Once daily | subcutaneous injection |
Instructions:
Round dose to nearest prefilled syringe dose of 300 micrograms or 480 micrograms. |
Day: 8
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
ondansetron | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. Alternative is dexamethasone 4 mg. |
|
PACLItaxel * | 80 mg/m² | intravenous | 60 minutes |
Instructions:
Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size. Please carry out graded challenge as per institutional policy. |
Day: 15
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
ondansetron | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. Alternative is dexamethasone 4 mg. |
|
PACLItaxel * | 80 mg/m² | intravenous | 60 minutes |
Instructions:
Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size. Please carry out graded challenge as per institutional policy. |
Cycles 3 to 4 - 21 days - cARBOplatin Q3W and PACLItaxel Q1W (no hypersensitivity pre-medications)
Day: 1
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
aprepitant | 125 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. |
|
dexamethasone * | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy with food. |
|
ondansetron | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. |
|
PACLItaxel * | 80 mg/m² | intravenous | 60 minutes |
Instructions:
Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size. Please carry out graded challenge as per institutional policy. |
cARBOplatin * | 6 AUC (area under the curve) | intravenous | 60 minutes |
Instructions:
Hypersensitivity risk increases with number of cycles of cARBOplatin. |
ondansetron | 8 mg | oral administration |
Instructions:
EIGHT hours after chemotherapy OR before bed. |
|
domperidone | 10 mg Three times daily | oral administration |
Instructions:
When required for nausea and/or vomiting. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics. |
Day: 2
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
aprepitant | 80 mg | oral administration |
Instructions:
ONCE daily in the morning. |
|
dexamethasone * | 8 mg | oral administration |
Instructions:
ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion. |
|
filgrastim | 5 microgram/kg Once daily | subcutaneous injection |
Instructions:
Round dose to nearest prefilled syringe dose of 300 micrograms or 480 micrograms. |
Day: 3
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
aprepitant | 80 mg | oral administration |
Instructions:
ONCE daily in the morning. |
|
dexamethasone * | 8 mg | oral administration |
Instructions:
ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion. |
|
filgrastim | 5 microgram/kg Once daily | subcutaneous injection |
Instructions:
Round dose to nearest prefilled syringe dose of 300 micrograms or 480 micrograms. |
Day: 4
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
filgrastim | 5 microgram/kg Once daily | subcutaneous injection |
Instructions:
Round dose to nearest prefilled syringe dose of 300 micrograms or 480 micrograms. |
Day: 5
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
filgrastim | 5 microgram/kg Once daily | subcutaneous injection |
Instructions:
Round dose to nearest prefilled syringe dose of 300 micrograms or 480 micrograms. |
Day: 6
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
filgrastim | 5 microgram/kg Once daily | subcutaneous injection |
Instructions:
Round dose to nearest prefilled syringe dose of 300 micrograms or 480 micrograms. |
Day: 8
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
ondansetron | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. Alternative is dexamethasone 4 mg. |
|
PACLItaxel * | 80 mg/m² | intravenous | 60 minutes |
Instructions:
Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size. Please carry out graded challenge as per institutional policy. |
Day: 15
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
ondansetron | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. Alternative is dexamethasone 4 mg. |
|
PACLItaxel * | 80 mg/m² | intravenous | 60 minutes |
Instructions:
Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size. Please carry out graded challenge as per institutional policy. |
Cycles 5 to 8 - 21 days - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W
Day: 1
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
olanzapine * | 5 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy.
|
|
aprepitant | 125 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. |
|
dexamethasone * | 12 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy with food. |
|
ondansetron | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. |
|
DOXOrubicin | 60 mg/m² | intravenous | 15 minutes |
Instructions:
Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration. |
CYCLOPHOSPHamide | 600 mg/m² | intravenous | 60 minutes | |
ondansetron | 8 mg | oral administration |
Instructions:
EIGHT hours after chemotherapy OR before bed. |
|
cycliZINE | 50 mg Three times daily | oral administration |
Instructions:
When required for nausea and/or vomiting.
|
Day: 2
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
olanzapine * | 5 mg | oral administration |
Instructions:
ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake. |
|
aprepitant | 80 mg | oral administration |
Instructions:
ONCE daily in the morning. |
|
dexamethasone * | 8 mg | oral administration |
Instructions:
ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion. |
Day: 3
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
olanzapine * | 5 mg | oral administration |
Instructions:
ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake. |
|
aprepitant | 80 mg | oral administration |
Instructions:
ONCE daily in the morning. |
|
dexamethasone * | 8 mg | oral administration |
Instructions:
ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion. |
Day: 4
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
olanzapine * | 5 mg | oral administration |
Instructions:
ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake. |
|
dexamethasone * | 8 mg | oral administration |
Instructions:
ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion. |
Supportive Care Factors
Factor | Value |
---|---|
Emetogenicity: | Variable |
Growth factor support: | Variable |
Hypersensitivity / Infusion related reaction risk: | Variable |
References
Novartis New Zealand Ltd. Paclitaxel Ebewe New Zealand Data Sheet 16 April 2020. https://www.medsafe.govt.nz/profs/Datasheet/p/PaclitaxelEbeweinj.pdf (Accessed 26 November 2020)
Castells, M.C., Matulonis, U.A., and Horton, TM. Infusion reactions to systemic chemotherapy. Savarese DMF and Feldweg AM, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com/contents/infusion-reactions-to-systemic-chemotherapy (Accessed 26 March 2021).
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.